Today is an exciting and transformative day for Jazz Pharmaceuticals as we complete the acquisition of GW Pharmaceuticals and its U.S. subsidiary, Greenwich Biosciences, a world leader in the science, development and commercialization of regulatory approved cannabinoid medicines.
With more than two decades spent pioneering cannabinoid science, GW Pharmaceuticals CEO Justin Gover and his team have built an impressive commercial portfolio and innovative pipeline of early and late-stage product candidates. Through this acquisition, we’re establishing a more robust and diversified focus across neuroscience and bringing together highly complementary expertise across sleep, epilepsies, movement disorders and psychiatry.
While this integration will not drive major changes in our day-to-day work, we welcome the opportunities it presents to have a positive impact on patients. Our teams share aligned cultures and are working collaboratively to ensure that the combined company leverages the strengths of both Jazz and GW so that we can build on our purpose to innovate to transform the lives of patients and their families, as well as to foster a great place to work for our employees.
Through the integration, our top priority is fulfilling our responsibility to patients and customers, and we remain committed to the therapeutic areas we have been focused on across Jazz and GW. Our combined organization will continue to focus on patients with high unmet needs and pursue innovative and differentiated therapies that establish new or better standards of care in neuroscience and oncology. With the addition of GW Pharmaceuticals, Jazz now has the world’s leading cannabinoid research platform and will continue development efforts to further evaluate cannabinoid science in new neuroscience areas of focus.
I’d like to say a big thank you to each of the team members across both organizations who have had a hand in preparing for an integration that minimizes disruption and creates a seamless experience patients, providers and payors; and ensures a great employee experience.
As we break ground with new medicines and look to meet the needs of more patients in the future, we remain as committed as ever to those we serve today. We feel fortunate to be combining two companies with a shared passion for, and track record of, developing differentiated therapies that advance science and transform the lives of patients and families around the world.
To learn more about the acquisition, visit: http://investor.jazzpharma.com/news?c=210227&p=irol-newsPage
الإبلاغ عن أثر جانبي
إذا كنت ترغب في الإبلاغ عن أثر جانبي مرتبط بالمنتجات الدوائية لشركة Jazz Pharmaceuticals، يُرجى إرسال بريد إلكتروني إلينا عبر الرابط التالي:
يُرجى تقديم أكبر قدر ممكن من المعلومات المتاحة.
تشمل المعلومات ذات الصلة ما يلي:
بتقديمك لتقريرك وتزويدنا ببيانات الاتصال الخاصة بك، فإنك تُقرّ وتوافق صراحةً على أنه يجوز لقسم السلامة الدوائية المحلي التواصل معك بغرض طلب معلومات إضافية أو توضيحات، إذا اعتُبر ذلك ضروريًا لتقييم التقرير ومتابعته.
يوضح إشعار الخصوصية الخاص بنا المتعلق باليقظة الدوائية والمعلومات الطبية وشكاوى المنتجات كيفية تعامل شركة Jazz Pharmaceuticals مع معالجة المعلومات الشخصية عند التعامل مع تقريرالأثر الجانبي الخاص بك، وهو متاح في مركز الخصوصية لدينا.
Report an Adverse Event
If you want to report a Adverse Event related to Jazz Pharmaceuticals medicinal products, then please send us an e-mail via this link:
Please provide as much available information as possible.
Relevant information includes:
By submitting your report and providing your contact details, you expressly acknowledge and agree that the local drug safety department may contact you for the purpose of requesting additional information or clarifications, should this be deemed necessary for the assessment and follow‑up of the report.
Our Privacy Notice for Pharmacovigilance, Medical Information and Product Complaints outlines how Jazz Pharmaceuticals handles the processing of personal information when dealing with your adverse event report and is available in our Privacy Center.
